Cochrane · systematic review · CD012565
Beta‐blockers in patients without heart failure after myocardial infarction
Safi, S, Sethi, NJ, Korang, SK, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
HeartAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
5
No studies
2
Included studies
NR
No studies 2 · 28.6%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 42.9%Moderate 2 · 28.6%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings at maximum follow‐up
Population: patients without heart failure
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality at maximum | RR 0.81 [0.73, 0.9] | 21 studies · 22085 participants | Moderate Downgraded: risk of bias |
Major cardiovascular events (cardiovascular mortality or non‐fatal myocardial infarction) at maximum | RR 0.72 [0.62, 0.83] | 15 studies · 14994 participants | Low Downgraded: risk of bias |
Serious adverse events at maximum | no estimate extracted | NR | No studies |
Quality of life | no estimate extracted | NR | No studies |
Angina pectoris at maximum | RR 1.04 [0.95, 1.13] | 5 studies · 7715 participants | Low Downgraded: risk of bias |
Cardiovascular mortality at maximum | RR 0.73 [0.61, 0.88] | 19 studies · 21763 participants | Low Downgraded: risk of bias |
Myocardial infarction at maximum | RR 0.76 [0.67, 0.86] | 19 studies · 19606 participants | Moderate Downgraded: risk of bias |